Streamlined quality assessments of new and improved vaccines and therapeutics for emerging variants of the SARS-CoV-2 virus outlined in 22 February US Food and Drug Administration guidance should expedite authorization once there is international agreement on when to use them.
Of particular concern is the B.1.351 variant seen first in South Africa because studies suggest it reduces efficacy of vaccines and therapeutics, some more than others. But equally worrisome are the many additional variants that are sure to emerge simply because of the nature and prevalence of the coronavirus
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?